Overview
Tumor of meninges (Orphanet code 252025) is a broad category of neoplasms that arise from the meningeal coverings of the brain and spinal cord. The meninges consist of three layers — the dura mater, arachnoid mater, and pia mater — and tumors originating from these structures encompass a heterogeneous group of neoplasms, the most common of which are meningiomas. However, this category also includes rarer tumors such as hemangiopericytomas (now classified as solitary fibrous tumors), melanocytic tumors of the meninges, and mesenchymal non-meningothelial tumors. These tumors primarily affect the central nervous system and can cause symptoms through compression of adjacent brain or spinal cord tissue. Clinical features vary depending on tumor location, size, and growth rate. Common symptoms include headaches, seizures, focal neurological deficits (such as weakness, sensory changes, or visual disturbances), cognitive changes, and signs of increased intracranial pressure. Spinal meningeal tumors may present with back pain, radiculopathy, or myelopathy. Most meningeal tumors occur sporadically, though some are associated with genetic predisposition syndromes such as neurofibromatosis type 2 (NF2), which involves mutations in the NF2 gene on chromosome 22q12. Treatment depends on the specific tumor type, grade, and location. Surgical resection is the primary treatment for most meningeal tumors, and complete removal can be curative for benign lesions. Radiation therapy, including stereotactic radiosurgery, is used for tumors that are not amenable to complete surgical resection or for higher-grade lesions. Chemotherapy has a limited role but may be considered for aggressive or recurrent tumors. Prognosis varies widely, from excellent for completely resected benign meningiomas to poor for high-grade malignant meningeal tumors. Regular follow-up imaging is recommended due to the risk of recurrence.
Variable
Can be inherited in different ways depending on the underlying gene
Adult
Begins in adulthood (age 18 or older)
FDA & Trial Timeline
10 eventsM.D. Anderson Cancer Center — NA
Medical College of Wisconsin — PHASE1
Alpha Biopharma (Jiangsu) Co., Ltd. — PHASE1
Guangzhou University of Traditional Chinese Medicine — NA
Sunnybrook Health Sciences Centre — NA
Peking University Cancer Hospital & Institute — PHASE1, PHASE2
Plus Therapeutics — PHASE1
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Henan Cancer Hospital — PHASE1, PHASE2
NYU Langone Health — NA
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Tumor of meninges.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Tumor of meninges at this time.
New trials open frequently. Follow this disease to get notified.
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Tumor of meninges.
Community
No community posts yet. Be the first to share your experience with Tumor of meninges.
Start the conversation →Latest news about Tumor of meninges
Disease timeline:
New recruiting trial: Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir
A new clinical trial is recruiting patients for Tumor of meninges
New recruiting trial: Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer
A new clinical trial is recruiting patients for Tumor of meninges
New recruiting trial: Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
A new clinical trial is recruiting patients for Tumor of meninges
New recruiting trial: Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
A new clinical trial is recruiting patients for Tumor of meninges
New recruiting trial: CSF and Blood Plasma Liquid Biopsy in Patients With Metastatic Solid Tumours and CNS Metastases or no CNS Metastases
A new clinical trial is recruiting patients for Tumor of meninges
New recruiting trial: Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
A new clinical trial is recruiting patients for Tumor of meninges
New recruiting trial: Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
A new clinical trial is recruiting patients for Tumor of meninges
New recruiting trial: Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer
A new clinical trial is recruiting patients for Tumor of meninges
New recruiting trial: Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases
A new clinical trial is recruiting patients for Tumor of meninges
New recruiting trial: Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease
A new clinical trial is recruiting patients for Tumor of meninges
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Tumor of meninges
What is Tumor of meninges?
Tumor of meninges (Orphanet code 252025) is a broad category of neoplasms that arise from the meningeal coverings of the brain and spinal cord. The meninges consist of three layers — the dura mater, arachnoid mater, and pia mater — and tumors originating from these structures encompass a heterogeneous group of neoplasms, the most common of which are meningiomas. However, this category also includes rarer tumors such as hemangiopericytomas (now classified as solitary fibrous tumors), melanocytic tumors of the meninges, and mesenchymal non-meningothelial tumors. These tumors primarily affect the
At what age does Tumor of meninges typically begin?
Typical onset of Tumor of meninges is adult. Age of onset can vary across affected individuals.
Which specialists treat Tumor of meninges?
25 specialists and care centers treating Tumor of meninges are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.